It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cervical cancer (CC) is the most common gynecological malignancy, whose cellular heterogeneity has not been fully understood. Here, we performed single-cell RNA sequencing (scRNA-seq) to survey the transcriptomes of 57,669 cells derived from three CC tumors with paired normal adjacent non-tumor (NAT) samples. Single-cell transcriptomics analysis revealed extensive heterogeneity in malignant cells of human CCs, wherein epithelial subpopulation exhibited different genomic and transcriptomic signatures. We also identified cancer-associated fibroblasts (CAFs) that may promote tumor progression of CC, and further distinguished inflammatory CAF (iCAF) and myofibroblastic CAF (myCAF). CD8+ T cell diversity revealed both proliferative (MKI67+) and non-cycling exhausted (PDCD1+) subpopulations at the end of the trajectory path. We used the epithelial signature genes derived from scRNA-seq to deconvolute bulk RNA-seq data of CC, identifying four different CC subtypes, namely hypoxia (S-H subtype), proliferation (S-P subtype), differentiation (S-D subtype), and immunoactive (S-I subtype) subtype. The S-H subtype showed the worst prognosis, while CC patients of the S-I subtype had the longest overall survival time. Our results lay the foundation for precision prognostic and therapeutic stratification of CC.
Single-cell RNA sequencing of cervical cancer reveals four different cancer subtypes and provides information on populations of cancer-associated fibroblasts as well as CD8+ T cell diversity.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Obstetrics and Gynecology Hospital of Fudan University, Department of Obstetrics and Gynecology, Shanghai, China (GRID:grid.412312.7) (ISNI:0000 0004 1755 1415)
2 Shanghai Jiao Tong University School of Medicine, Precision Research Center for Refractory Diseases, Institute for Clinical Research, Shanghai General Hospital, Shanghai, China (GRID:grid.16821.3c) (ISNI:0000 0004 0368 8293); Shanghai University, Laboratory of Molecular Neural Biology, School of Life Sciences, Shanghai, China (GRID:grid.39436.3b) (ISNI:0000 0001 2323 5732)
3 Obstetrics and Gynecology Hospital of Fudan University, Department of Pathology, Shanghai, China (GRID:grid.412312.7) (ISNI:0000 0004 1755 1415)
4 Shanghai Jiao Tong University School of Medicine, Precision Research Center for Refractory Diseases, Institute for Clinical Research, Shanghai General Hospital, Shanghai, China (GRID:grid.16821.3c) (ISNI:0000 0004 0368 8293)